Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, BillyBahama, GoldenMind
Search This Board: 
Last Post: 3/24/2019 2:33:46 AM - Followers: 769 - Board type: Free - Posts Today: 1



US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here: https://www.ncbi.nlm.nih.gov/pubmed/21982657).  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here: https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm

USRM - Daily Candlesticks

SUNRISE, Fla.Jan. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement.  Details of the procedure and the results are featured in the January issue of Men's Healthon newsstands now. Link here!!! ----->>>>https://www.prnewswire.com/news-releases/usrm-stem-cell-treatment-shows-promise-in-enhancing-erectile-function-300578817.html

Ben Greenfield posted (Jan 16th, 2018) video at US Stem Cell clinic in Florida    https://www.instagram.com/p/BeCDtYqFX8I/?hl=en&taken-by=bengreenfieldfitness

Expecting Ben Greenfield's article to be found here once written any day now... https://www.menshealth.com/author/ben-greenfield

Press Releases:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Annual Report (10-k) 03/13/2019 04:04:18 PM
USRM News: Current Report Filing (8-k) 02/01/2019 04:02:42 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/07/2018 04:30:47 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/07/2018 04:29:54 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 12/07/2018 04:22:17 PM
#99996  Sticky Note https://seekingalpha.com/filing/4402343?app=1 Resq10 03/13/19 04:36:20 PM
#94862  Sticky Note Is this how USRM says the FDA / Gobsmacked01 05/16/18 09:43:09 PM
#85293  Sticky Note $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 GoldenMind 12/04/17 04:27:33 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#100171   Something was happening 25th emit 03/24/19 02:33:46 AM
#100170   Business as usual at the clinics and I Xpecht 03/23/19 08:32:52 PM
#100169   Murphy is actually in the Comella vs US a1tellem 03/23/19 06:57:39 PM
#100168   Attorney: Gradel PERMANENT INJUNCTION...MEDIATION FAILS..oh no.... Hornet Driver 03/23/19 06:27:29 PM
#100167   Roger Stone is there. Kind of crazy lol a1tellem 03/23/19 05:44:46 PM
#100165   Had to update my docket!!! Thanks for the update! a1tellem 03/22/19 07:34:57 PM
#100164   this was filed March 22 titled Mediators report. wallas2g1 03/22/19 07:32:46 PM
#100163   The last update is on the 12th. On the a1tellem 03/22/19 07:19:21 PM
#100162   Pacer. It's all there. wallas2g1 03/22/19 07:16:16 PM
#100161   $USRM .. +3 million to OS BillyBahama 03/22/19 07:11:27 PM
#100160   When and where did you see the mediation a1tellem 03/22/19 06:22:22 PM
#100159   Mediation report out. No agreement between the parties wallas2g1 03/22/19 05:33:21 PM
#100158   I'll be here when this fuse it lit. JoeJoeyoyo 03/22/19 04:51:55 PM
#100157   Yep! that's when I will load up at .0001 weesnel 03/22/19 03:36:28 PM
#100156   Wait for the Judge period. boardbrain1 03/22/19 03:02:38 PM
#100154   Sounds good to me too! 4toSchool 03/22/19 01:43:49 PM
#100153   Sounds good to me! Thanks for sharing your Hippycowboy 03/22/19 11:46:25 AM
#100151   An article from a bias attorney means nothing FIREST1 03/22/19 11:09:35 AM
#100149   Great Points!!! 4toSchool 03/21/19 07:22:13 PM
#100148   KEEP IN MIND THEY WERE NOT EVEN DOING a1tellem 03/21/19 07:21:24 PM
#100147   With that rebuttal, I'll be buying more shares BillyBahama 03/21/19 06:23:26 PM
#100146   US STEM CELL CLINIC the FDA and INMVHO 4toSchool 03/21/19 05:16:16 PM
#100145   !!!!! a1tellem 03/21/19 05:05:22 PM
#100144   LMAO BS, "There is a HUGE difference between Hornet Driver 03/21/19 04:53:17 PM
#100143   BS, The "information" provided in the post are 4toSchool 03/21/19 04:35:42 PM
#100142   Help me understand how the situation described as 4toSchool 03/21/19 04:30:25 PM
#100141   There is a HUGE difference between a "CLINIC 4toSchool 03/21/19 04:07:20 PM
#100140   Here is more information on Theodore Gradel reposted 4toSchool 03/21/19 03:25:29 PM
#100139   With all this information about him was available 4toSchool 03/21/19 03:04:05 PM
#100138  Restored LMAO QUOTE, "My Guess: Ted backed out of Hornet Driver 03/21/19 02:59:41 PM
#100137   Thanks for the insight. Also this isn’t “breaking a1tellem 03/21/19 02:32:04 PM
#100135   USRM: ATTORNEY ARTICLE - ONE DEFENDANT SIGNED DECREE !! Hornet Driver 03/21/19 01:43:46 PM
#100134   Sounds good to me! Thanks for continued updates! Hippycowboy 03/20/19 05:26:36 PM
#100133   Pitiful Volume. Calm before storm. kaos2k 03/20/19 04:12:30 PM
#100132   Let’s Hope So!!! Resq10 03/20/19 04:11:07 PM
#100131   FDA can't stop PROGRESS.. Americans' interest in stem BillyBahama 03/20/19 03:40:14 PM
#100130   I just bought a small # of $USRM 4toSchool 03/20/19 03:22:03 PM
#100129   Maybe when it starts trading again itll be FIREST1 03/20/19 03:10:48 PM
#100128   Very Strange. 100% buys. I've never seen this 4toSchool 03/20/19 02:57:29 PM
#100127   Posted on facebook, no trading since before noon, kkdman 03/20/19 02:01:08 PM
#100124   Ditto Resq10 03/20/19 11:05:14 AM
#100123   I’m curious as to what happens to our Cashman17 03/20/19 10:53:19 AM
#100122   Thank you a1tellem and NoMoDo for sharing your BillyBahama 03/20/19 10:48:28 AM
#100121   Sounds good to me too! 4toSchool 03/20/19 10:38:59 AM
#100120   DING DING DING!!!! Same thoughts Np Nomo, thank YOU for a1tellem 03/20/19 10:35:22 AM
#100119   $USRM .0265 BillyBahama 03/20/19 10:17:45 AM
#100118   I think you may be right. I NoMoDo 03/20/19 10:13:14 AM
#100117   Sounds good to me! Hippycowboy 03/20/19 09:15:33 AM
#100116   This case won't make it to a jury BillyBahama 03/20/19 08:56:29 AM
#100113   25 MAR RESPONSE DUE FOR BOTH MOTIONS FOR Devils Tower 03/19/19 07:10:15 PM